FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2989717069> ?p ?o ?g. }

• W2989717069 endingPage "896.e6" @default.
• W2989717069 startingPage "885" @default.
• W2989717069 abstract "BackgroundOral immunotherapy (OIT) can successfully desensitize many peanut-allergic subjects, but clinical tolerance diminishes over time on discontinuation, or low-dose maintenance, of peanut. Therefore, to improve the efficacy and sustainability of such therapy, we sought to identify biomarkers and clinical tools that can predict therapeutic outcomes and monitor treatment responses.ObjectiveWe evaluated whether basophil activation in whole blood, and plasma levels of peanut-specific immunoglobulins, are useful biomarkers for peanut OIT.MethodsWe longitudinally measured, before, during, and after OIT, basophil activation in whole blood ex vivo in response to peanut stimulation, and peanut-specific IgE (sIgE) and peanut-specific IgG4 (sIgG4), in a large, single-site, double-blind, randomized, placebo-controlled, phase 2 peanut OIT study. We compared basophil responsiveness and peanut-specific immunoglobulins between those who were clinically reactive and those who were tolerant to peanut oral challenges.ResultsPeanut OIT significantly decreased basophil activation, peanut sIgE, Ara h 1, Ara h 2, and Ara h 3 IgE levels, and sIgE/total IgE, but increased sIgG4/sIgE. Participants who became reactive to 4 g of peanut 13 weeks off active OIT exhibited higher peanut-induced basophil activation ex vivo and higher peanut sIgE levels and sIgE/total IgE, but lower sIgG4/sIgE. Notably, participants entering the study with low basophil responsiveness were more likely to achieve treatment success. Substantial suppression of basophil activation was required to maintain long-term clinical tolerance after peanut OIT.ConclusionsAssessments of peanut-induced basophil activation and peanut-specific immunoglobulins can help to predict treatment outcomes, and to differentiate transient desensitization versus sustained unresponsiveness after OIT. Oral immunotherapy (OIT) can successfully desensitize many peanut-allergic subjects, but clinical tolerance diminishes over time on discontinuation, or low-dose maintenance, of peanut. Therefore, to improve the efficacy and sustainability of such therapy, we sought to identify biomarkers and clinical tools that can predict therapeutic outcomes and monitor treatment responses. We evaluated whether basophil activation in whole blood, and plasma levels of peanut-specific immunoglobulins, are useful biomarkers for peanut OIT. We longitudinally measured, before, during, and after OIT, basophil activation in whole blood ex vivo in response to peanut stimulation, and peanut-specific IgE (sIgE) and peanut-specific IgG4 (sIgG4), in a large, single-site, double-blind, randomized, placebo-controlled, phase 2 peanut OIT study. We compared basophil responsiveness and peanut-specific immunoglobulins between those who were clinically reactive and those who were tolerant to peanut oral challenges. Peanut OIT significantly decreased basophil activation, peanut sIgE, Ara h 1, Ara h 2, and Ara h 3 IgE levels, and sIgE/total IgE, but increased sIgG4/sIgE. Participants who became reactive to 4 g of peanut 13 weeks off active OIT exhibited higher peanut-induced basophil activation ex vivo and higher peanut sIgE levels and sIgE/total IgE, but lower sIgG4/sIgE. Notably, participants entering the study with low basophil responsiveness were more likely to achieve treatment success. Substantial suppression of basophil activation was required to maintain long-term clinical tolerance after peanut OIT. Assessments of peanut-induced basophil activation and peanut-specific immunoglobulins can help to predict treatment outcomes, and to differentiate transient desensitization versus sustained unresponsiveness after OIT." @default.
• W2989717069 created "2019-12-05" @default.
• W2989717069 creator A5003883433 @default.
• W2989717069 creator A5004151297 @default.
• W2989717069 creator A5010135113 @default.
• W2989717069 creator A5028760615 @default.
• W2989717069 creator A5039188376 @default.
• W2989717069 date "2020-03-01" @default.
• W2989717069 modified "2023-10-18" @default.
• W2989717069 title "Sustained successful peanut oral immunotherapy associated with low basophil activation and peanut-specific IgE" @default.
• W2989717069 cites W163740715 @default.
• W2989717069 cites W1650397053 @default.
• W2989717069 cites W1969953062 @default.
• W2989717069 cites W1977800771 @default.
• W2989717069 cites W1982997444 @default.
• W2989717069 cites W1986547754 @default.
• W2989717069 cites W1991498260 @default.
• W2989717069 cites W1991782145 @default.
• W2989717069 cites W1994095603 @default.
• W2989717069 cites W2005851413 @default.
• W2989717069 cites W2012513978 @default.
• W2989717069 cites W2012769899 @default.
• W2989717069 cites W2022764839 @default.
• W2989717069 cites W2027046805 @default.
• W2989717069 cites W2046836171 @default.
• W2989717069 cites W2046984705 @default.
• W2989717069 cites W2061228058 @default.
• W2989717069 cites W2079909497 @default.
• W2989717069 cites W2091469647 @default.
• W2989717069 cites W2097001981 @default.
• W2989717069 cites W2118587943 @default.
• W2989717069 cites W2121365217 @default.
• W2989717069 cites W2129147449 @default.
• W2989717069 cites W2148274412 @default.
• W2989717069 cites W2162344297 @default.
• W2989717069 cites W2300608583 @default.
• W2989717069 cites W2305061550 @default.
• W2989717069 cites W2491611941 @default.
• W2989717069 cites W2493558455 @default.
• W2989717069 cites W2626389363 @default.
• W2989717069 cites W2766193871 @default.
• W2989717069 cites W2780090021 @default.
• W2989717069 cites W2793109512 @default.
• W2989717069 cites W2886919876 @default.
• W2989717069 cites W2888603931 @default.
• W2989717069 cites W2895561458 @default.
• W2989717069 cites W2899329002 @default.
• W2989717069 cites W2900153908 @default.
• W2989717069 cites W2906163223 @default.
• W2989717069 cites W2906223120 @default.
• W2989717069 cites W2914471475 @default.
• W2989717069 cites W2942283768 @default.
• W2989717069 cites W2947397217 @default.
• W2989717069 cites W2966382271 @default.
• W2989717069 cites W2972623358 @default.
• W2989717069 cites W4211171313 @default.
• W2989717069 cites W4249744927 @default.
• W2989717069 doi "https://doi.org/10.1016/j.jaci.2019.10.038" @default.
• W2989717069 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6957313" @default.
• W2989717069 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31805311" @default.
• W2989717069 hasPublicationYear "2020" @default.
• W2989717069 type Work @default.
• W2989717069 sameAs 2989717069 @default.
• W2989717069 citedByCount "73" @default.
• W2989717069 countsByYear W29897170692019 @default.
• W2989717069 countsByYear W29897170692020 @default.
• W2989717069 countsByYear W29897170692021 @default.
• W2989717069 countsByYear W29897170692022 @default.
• W2989717069 countsByYear W29897170692023 @default.
• W2989717069 crossrefType "journal-article" @default.
• W2989717069 hasAuthorship W2989717069A5003883433 @default.
• W2989717069 hasAuthorship W2989717069A5004151297 @default.
• W2989717069 hasAuthorship W2989717069A5010135113 @default.
• W2989717069 hasAuthorship W2989717069A5028760615 @default.
• W2989717069 hasAuthorship W2989717069A5039188376 @default.
• W2989717069 hasBestOaLocation W29897170691 @default.
• W2989717069 hasConcept C126322002 @default.
• W2989717069 hasConcept C141105273 @default.
• W2989717069 hasConcept C150903083 @default.
• W2989717069 hasConcept C159654299 @default.
• W2989717069 hasConcept C170493617 @default.
• W2989717069 hasConcept C203014093 @default.
• W2989717069 hasConcept C207001950 @default.
• W2989717069 hasConcept C26291073 @default.
• W2989717069 hasConcept C2777456892 @default.
• W2989717069 hasConcept C2778012357 @default.
• W2989717069 hasConcept C2778715236 @default.
• W2989717069 hasConcept C2779176990 @default.
• W2989717069 hasConcept C2779779143 @default.
• W2989717069 hasConcept C3018710434 @default.
• W2989717069 hasConcept C71924100 @default.
• W2989717069 hasConcept C86803240 @default.
• W2989717069 hasConceptScore W2989717069C126322002 @default.
• W2989717069 hasConceptScore W2989717069C141105273 @default.
• W2989717069 hasConceptScore W2989717069C150903083 @default.
• W2989717069 hasConceptScore W2989717069C159654299 @default.
• W2989717069 hasConceptScore W2989717069C170493617 @default.
• W2989717069 hasConceptScore W2989717069C203014093 @default.

• next